Malignant Melanoma | Disease Landscape & Forecast | G7 | 2022
The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy (Bristol Myers Squibb), and Tecentriq (Roche / Genentech; U.S. only), as well as BRAF/MEK inhibitor combinations such as Roche / Genentech’s Zelboraf plus Cotellic, Novartis’s Tafinlar plus Mekinist, and Pfizer / Array BioPharma’s Braftovi plus Mektovi, has significantly changed the treatment landscape for malignant melanoma in both the resectable and metastatic settings. Nonetheless, opportunities remain for novel agents specifically targeting the underrepresented BRAF wild-type unresectable or metastatic population. With the expected introduction of novel agents and combination regimens, the malignant melanoma treatment paradigm will continue to evolve.
Questions answered:
- How large are the clinically and commercially relevant malignant melanoma drug-treatable populations? Will drug treatment rates increase over the forecast period?
- What is the current treatment landscape in malignant melanoma? Which currently approved drugs are the most prescribed and why?
- Which drugs in late-phase development are poised to change the treatment of malignant melanoma and how? What sales / uptake could these drugs secure in the malignant melanoma market?
- What are the key drivers of / constraints in the malignant melanoma therapy market, and how will the market evolve over the forecast period?
Content highlights
Geographies: United States, EU5, Japan.
Primary research: 16 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other Clarivate research.
Epidemiology: Incidence of malignant melanoma by country, segmented by BRAF mutation status, disease stage, and line of therapy.
Forecast: 10-year, annualized, drug-level sales and patient share of key malignant melanoma therapies through 2031, segmented by brands / generics / biosimilars and epidemiological subpopulations.
Emerging therapies: Phase III: 4 drugs; Phase II: 3 drugs; coverage of select early-phase products.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast features continual updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
